Area of research
Behavioral Neuroscience · Pharmacology
Research interest
fuels the discovery and delivery of next-generation preventions, diagnoses, treatments and cures. LET'S GO In This Section Overview Innovation & Entrepreneurship Research Resources Strategic Research Programs Faculty Research Labs Clinical Trials More Information ATTEND Research Events Explore Latest News & Discoveries Research Commercialization at UT MEET
Impact of Inflammation on White Matter Integrity and Functional Connectivity in Chronic Major Depressive Disorder.
Psychedelic therapeutics in psychiatric conditions.
Relationships Among Dementia, Parental Death, and Other Adverse Childhood Experiences: Systematic Review and Meta-Analysis.
Implementing artificial intelligence (AI) to facilitate health outcomes in mood disorders: Application versus aspiration.
Correction: Psychedelic therapeutics in psychiatric conditions.
TMS in adolescent depression: A milestone FDA clearance.
Intravenous Brexanolone for the Treatment of Posttraumatic Stress Disorder: A Case Report.
Altered amygdala and striatal responsivity and prediction error encoding of temporal reward dynamics in post-trauma psychopathology.
Augmenting extinction with counterconditioning strengthens and sustains neural safety representations in PTSD.
Trends in the psychedelic renaissance: applying artificial intelligence to measure media portrayal of psychedelic drugs in the 21st century.
History of interpersonal trauma exposure is a robust risk factor for alcohol and substance use disorders during adolescence.
Exploring resource profiles among trauma exposed youth: An identity-focused, cultural, and person-centered approach.
Validity of the PHQ-9A as a self-report screener for major depressive disorder in youth ages 10-12 years.
The Use of Vagus Nerve Stimulation (VNS) in the Management of Patients with Difficult-to-Treat Major Depressive Disorder (MDD): An Expert Consensus Statement.
Childhood Maltreatment in the Context of Familial Bipolar I Disorder Risk Predicts Major Depressive Disorder in Adolescents
Anhedonia in patients with major depressive disorder (MDD): state-of-the-art consensus review
The Role of GABA in the Pathophysiology and Treatment of Anxiety Disorders
Duloxetine for the Treatment of Major Depressive Disorder
Low-intensity transcranial focused ultrasound amygdala neuromodulation: a double-blind sham-controlled target engagement study and unblinded single-arm clinical trial.
MDMA and MDMA-Assisted Therapy.
Psilocybin: From Psychiatric Pariah to Perceived Panacea.
Early Life Stress and Substance Use Disorders: Underlying Neurobiology and Pathways to Adverse Outcomes.
Prediction of individual patient outcomes to psychotherapy vs medication for major depression
Sex Differences in the Associations Among Early Life Adversity, Inflammation, and Cognition.
Genetic Correlates of Treatment-Resistant Depression.
Prediction of individual patient outcomes to psychotherapy vs medication for major depression.
Low responsiveness of machine learning models to critical or deteriorating health conditions.
Psychedelics in Psychiatry: Oh, What A Trip!
ANK3 as a Novel Genetic Biomarker for Liafensine in Treatment-Resistant Depression: The ENLIGHTEN Randomized Clinical Trial.
Treatment resistant depression: Socio-demographic characteristics, comorbidity and treatment patterns from the All of Us Research Program.